Global Latent TB Testing Market Size, Trend & Opportunity Analysis Report, by Brand (QFT-Plus), Test Type (Tuberculin Skin Test, Interferon Gamma Released Assay), Application (Household Contacts with Pulmonary TB, PLHIV, Others), End Use (Diagnostic Laboratories, Hospitals/Clinics, Academic & Research Institutions), and Forecast, 2025-2035
Global Latent TB Testing Market Size, Opportunity Analysis and Forecast, 2025-2035
Market Definition and Introduction
The Global Latent TB Testing Market was valued at USD 1.75 billion in 2024 and is anticipated to reach USD 3.22 billion by 2035, expanding at a CAGR of 5.77% during the forecast period 2025-2035. Increasing global demand for tuberculosis elimination has put latent TB testing at the forefront of public health strategies. This is when the world aligns towards the WHO End TB Strategy targets; latent TB testing becomes a critical preventive tool to identify people at risk before the actual disease starts manifesting. This redefinition of priorities has brought about a shift in diagnostic priorities, which requires healthcare systems, policymakers, and global health agencies to incorporate testing initiatives into broader TB control programmes.
On the demand side, there has been an increased incidence of TB in countries of high burden, especially among such vulnerable groups as people living with HIV (PLHIV) and close contacts of pulmonary TB patients. This has spurred the need for reliable diagnostic solutions. For their part, up-and-coming technologies ensure accurate, fast and scalable screening improvements by putting investments into further test improvement. Changes are also being propelled by rising global mobility and risk of cross-border TB transmission, demanding consistent testing for latent TB across high-burden areas and those considered low-burden.
On the supply side, established diagnostic players are pouring R&D resources into developing extremely sensitive and specific assays, besides addressing operational problems of accessibility and affordability. Currently, the push towards decentralised test solutions coupled with digital diagnostic platforms and point-of-care innovations is widening the reach of the market towards underserved geographies. Such funding initiatives and collaborative health projects set up by governments and NGOs are reshaping the scenario within the market, offering unique opportunities for stakeholders but simultaneously posing challenges around scalability, affordability, and infrastructure readiness.
Recent Developments in the Industry
- In June 2024, QIAGEN joined forces with the Foundation for Innovative New Diagnostics (FIND) to increase the availability of interferon gamma release assays (IGRAs) across sub-Saharan Africa. Both organisations are interested in working to lower cost barriers and improve the scalability of their testing.
- In March 2023, Oxford Immunotec set up the next generation of the T-SPOT.TB test with increased accuracy for immunocompromised patients, further entrenching the company's leadership in this IGRA market segment.
- In July 2024, the US FDA granted breakthrough designation to a novel digital TB test developed by Thermo Fisher Scientific, facilitating expedited approval pathways to support latent TB screening in vulnerable populations.
- In April 2025, bioM-rieux reported investing USD 150 million to enhance its diagnostic manufacturing facility in France, an effort that will scale IGRA test production for the European and Asian markets.
- In September 2024, Abbott Laboratories increased the reach of its TB diagnostics portfolio in Latin America, facilitated through the collection of accounts via a strong distribution network to include traditionally inaccessible healthcare systems.
- In January 2025, ARKRAY Inc. released a portable diagnostic platform based on the Interferon-Gamma-Releasing Assay, designed for use in low-resource areas to improve results speed and reduce dependency on centralised laboratories.
Market Dynamics
Increasing latent TB tests are also taking place due to increasing numbers of TB infections.
The high transmission rates of TB in some areas, combined with an aggravated crisis in low-income countries, create an urgent demand for latent TB diagnostics. Every year, more than 10 million active cases of TB are reported, and the number of latent cases is much larger. Governments and the global health agencies are ramping up screening campaigns. Early identification of latent TB is critical in TB control because if untreated, it can serve as a significant reservoir for future outbreaks. Increasing recognition that preventive testing is a public
health imperative continuously fuels steady growth.
High implementation costs and the constraint of infrastructure, however, restrict the broad-based implementation of latent TB testing.
The clinical evidence supporting latent TB screening is robust, yet cost and lack of infrastructure still serve as major impediments. The high cost of tests such as IGRAs, compared to traditional tuberculin skin tests, has limited adoption in resource-constrained settings. Also, additional operational complexities arise from the need for laboratory infrastructure, trained personnel, and cold-chain logistics. They pose significant challenges in scaling up the testing programmes where the TB burden is disproportionately high and action is lacking in many low-income countries, which also have limited healthcare budgets.
The impossibility of differentiating latent infection from active TB renders complications in diagnostic strategies.
Unlike the above methods, current testing strategies are efficient for diagnosing latent TB infections; However, these methods are not able to differentiate between latent and active disease. This/the limit in diagnosis, which would have a complicating effect on treatment pathways for people living in high-burden settings where latent infection coexists with active TB. The absence of clinical clarity can lead to over- or under-treatment, straining not only health care resources, but patient compliance as well. Hence, the demand for increasingly sophisticated biomarkers and advanced diagnostic technologies remains a critical unmet need in this market.
Emerging opportunities due to increasing demand for preventive health create avenues for innovation in TB diagnostics.
Changing lifestyle and preventive healthcare policies are creating the enabling environment for growth in innovation, which is also evidenced by the WHO recommendations for testing high-risk populations for latent TB. Incorporation of digital platforms for test interpretation, decentralised point-of-care diagnosis, and AI-powered data analytics presents excellent opportunities for manufacturers. That was not all, as governments also funded collaborative initiatives of diagnostic companies to expand the pathway of making testing available.
Digital and hybrid trends in testing will shape the future of latent TB diagnostics.
Emerging trends include the incorporation of digital health platforms for test reporting and monitoring, which redefines the diagnostic landscape. Current hybrid testing combines skin-based assays with interferon-based assays and may further improve accuracy as well as the patient experience. An expansion of mobile health-supported remote testing programs will redefine market adoption patterns in rural areas and those not well-served.
Attractive Opportunities in the Market
- Bio-diagnostic innovation - Advanced interferon gamma assays driving improved diagnostic accuracy in high-risk populations
- Portable testing platforms - Decentralised, field-ready diagnostics expanding accessibility in low-resource and rural settings
- Pharma-diagnostic synergy - Integration of testing into TB treatment protocols, accelerating precision preventive healthcare
- Government health initiatives - Expanded screening programmes backed by public funding strengthen market penetration
- Digital health integration - Mobile reporting and AI-driven analytics streamline test interpretation and monitoring
- Emerging market growth - Rapid adoption across Asia-Pacific and Africa driven by TB burden and public investment
- Regulatory acceleration - Expedited approvals for novel tests, enhancing speed-to-market for diagnostic innovations
- Collaborative partnerships - Cross-industry alliances boosting R&D investment in next-generation TB testing tools
- NGO and donor funding - Increased global health financing fuelling testing access in endemic regions
- Sustainable diagnostics - Eco-friendly and cost-effective test solutions gaining traction among global healthcare stakeholders
Report Segmentation
By Brand: QFT-Plus
By Test Type: Tuberculin Skin Test, Interferon Gamma Released Assay
By Application: Household Contacts with Pulmonary TB, PLHIV, Others
By End Use: Diagnostic Laboratories, Hospitals/Clinics, Academic & Research Institutions
By Region: North America (U.S., Canada, Mexico), Europe (UK, Germany, France, Spain, Italy, Spain, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea, Rest of Asia-Pacific), LAMEA (Brazil, Argentina, UAE, Saudi Arabia (KSA), Africa Rest of Latin America)
Key Market Players: QIAGEN, Oxford Immunotec, bioM-rieux, Thermo Fisher Scientific, ARKRAY Inc., F. Hoffmann-La Roche Ltd., Abbott Laboratories, Creative Diagnostics, Bio-Techne Corporation, and Danaher Corporation.
Report Aspects
Base Year: 2024
Historic Years: 2022, 2023, 2024
Forecast Period: 2024-2035
Report Pages: 293
Dominating Segments
Interferon Gamma Release Assays are leading in new dynamics for diagnostic accuracy and preventive healthcare efforts on the international scene.
Interferon Gamma Release Assays (IGRAs) are fast becoming a gold standard in latent TB testing due to superior specificity and accuracy when compared to conventional tuberculin skin tests. In comparison with skin tests, IGRAs minimise cross-reactivity with BCG vaccination, a major advantage in countries where BCG is given universally. Robust laboratory workflows with rapid turnaround times serve to complement their widespread appeal in both clinical and research situations. As early detection of TB has grabbed the attention of governments and healthcare bodies, IGRAs are becoming the method of choice in wealthier countries with well-founded healthcare systems. In developing countries, IGRA works worldwide through collaborations, while IGRA continues to evolve, enhancing performance in diagnostic accuracy for immunocompromised populations.
Diagnostic Laboratories still lead the end-use segment to anchor their dominance based on infrastructure and testing capacity.
Diagnostic laboratories remain the end-use giants of the latent TB testing market, thanks to their enhanced infrastructure, scalability, and capacity in running complex assays. These laboratories have centralised functions to process vast test numbers and are considered indispensable in national screening programs and clinical research work. The positioning of laboratories to also integrate IGRAs and tuberculin into multi-disease testing workflows makes this system more efficient. Partnering with interested parties from both public and private sectors with laboratories is building capacity for advanced diagnostics, including digital reporting and patient data analytics. The inherent strength of this competitiveness is translated into the fact that they deal with testing considered vulnerable and high-volume populations, thus securing their centrality in TB control strategies.
PLHIV applications have a huge share of business, which further emphasises the testing process's role in the management of vulnerable patients.
Among applications, PLHIV (persons living with HIV) are one of the most outstanding and fast-emerging arsenals in latent TB testing because of the increased risk of TB from latent to active features, which makes early diagnosis a requisite for preventive therapy. Testing strategies for PLHIV have increasingly received attention on the global health agenda, and the emphasis on regular screening in this group by WHO and national TB programmes is ever-growing. Advanced diagnostics, donor financing arrangements, and specific NGO-led awareness campaigns are pushing the wrapped testing rate of PLHIV. As ART coverage extends globally, latent TB testing in HIV patients will likely augment even further, thereby further consolidating the stronger position of this segment in the overall market.
Key Takeaways
- IGRA dominance - Interferon gamma assays are increasingly preferred for their precision over tuberculin skin testing
- Laboratory centrality - Diagnostic labs maintain a stronghold as the primary hubs for TB testing capacity and accuracy
- PLHIV focus - High-risk HIV-positive populations remain critical drivers of screening adoption and treatment linkage
- Digital health boost - Mobile integration and AI-supported interpretation reshape diagnostic efficiency and accessibility
- Emerging market momentum - Asia-Pacific and Africa rapidly expand TB testing infrastructures with government funding
- Regulatory support - Expedited approvals for diagnostic tools accelerate time-to-market for advanced testing platforms
- Public-private synergy - Collaborations enhance accessibility and affordability of high-quality TB diagnostic services
- Preventive healthcare shift - Increasing emphasis on early detection repositions latent testing as a public health priority
- Innovation drive - Development of portable and decentralised testing devices improves outreach in rural and remote areas
- Sustainability focus - Affordable and eco-friendly diagnostic solutions are increasingly favoured in donor-driven health markets
Regional Insights
North America leads healthcare market with advanced infrastructure, strict regulatory approvals, and strategic growth
North America, thus, remains a force to reckon with when it comes to latent TB testing. Its strong health care infrastructure, advanced
diagnostic adoption, and supportive government policies create a very enabling environment. The country that stands out is the United States; demand is driven by mass screening of immigrants, and through active partnership between government agencies and these companies, diagnostics. Such regulatory frameworks, including the breakthrough designation for novel TB diagnostics by the FDA, have contributed to a faster pace in moving to newer testing platforms. In addition, the involvement of digital health platforms in diagnostic workflows is ensuring deeper penetration of the market among clinical and research institutions, thus ensuring ongoing North American dominance.
Europe leads innovations in green and efficient diagnostic practices while also undertaking high-burden migrant screening.
Europe has carved out its space as a leader in innovation for latent testing in this area, significantly focusing on precision diagnosis and energy-efficient laboratory practices. Countries such as Germany, France, and the UK are ramping up investments towards building the integration of digital diagnostics and next-generation TB tests into national elimination programs. The migrant refugee population also has become somewhat epidemic in TB, creating a space for some governments to increase targeted screening programs. Tough regulations from the European Medicines Agency, along with huge funding into clinical trials and academic research, have been furthering the region's occupation of diagnostic innovation.
Asia-Pacific: The fastest-growing market because of the processes of industrialisation, urbanisation, and the rising TB burden.
Expectations predict that the Asia-Pacific will be the fastest-growing market in the coming stretches, spurred by increasing investments in the healthcare infrastructure and even greater TB burdens. Countries - among them India, China, and South Korea - are aggressively pushing through public health campaigns, funding from donors, and launching initiatives through national immunisation programs to increase their TB control efforts. A solid base for future growth in pharmaceutical manufacturing in the region will further drive diagnostic adoption in research and clinical development. For instance, governments are beginning to motivate the adoption of portable diagnostic solutions that are more affordable to ensure coverage of poor and rural populations. This will speed up market penetration.
LAMEA continues to advance through donor-driven initiatives and expanding healthcare access across regions with high prevalence.
This fact, combined with the continued rise in donor-driven initiatives, makes Latin America, the Middle East, and Africa, all put together, a great latent TB testing potential field owing to the high disease prevalence. In sub-Saharan Africa, the major demographics for HIV, AIDS, and other infectious diseases belong to PLHIV populations, to which NGOs and global health organisations mobilise funds for screening campaigns. In Latin America, Brazil and Argentina are heading investments in diagnostic infrastructures, while countries such as Saudi Arabia are looking at migrant health programs in the Middle East. Even considering the institutional issues, the access expansion is happening very quickly in the region, attributed to global collaboration and financial pledges, keeping the growth potential steady.
Key Benefits for Stakeholders
- The report offers a quantitative assessment of market segments, emerging trends, projections, and market dynamics for the period 2024 to 2035.
- The report presents comprehensive market research, including insights into key growth drivers, challenges, and potential opportunities.
- Porter's Five Forces analysis evaluates the influence of buyers and suppliers, helping stakeholders make strategic, profit-driven decisions and strengthen their supplier-buyer relationships.
- A detailed examination of market segmentation helps identify existing and emerging opportunities.
- Key countries within each region are analysed based on their revenue contributions to the overall market.
- The positioning of market players enables effective benchmarking and provides clarity on their current standing within the industry.
- The report covers regional and global market trends, major players, key segments, application areas, and strategies for market expansion.
Frequently Asked Question(FAQ) :
Interferon Gamma Release Assays (IGRAs) are the leading diagnostic segment. They are increasingly preferred over traditional Tuberculin Skin Tests (TST) due to their superior specificity, faster turnaround times, and ability to minimize cross-reactivity with the BCG vaccination.
The market is characterized by several prominent diagnostic and life sciences companies, including QIAGEN, Oxford Immunotec, bioMérieux, Thermo Fisher Scientific, ARKRAY Inc., F. Hoffmann-La Roche Ltd., Abbott Laboratories, Creative Diagnostics, Bio-Techne Corporation, and Danaher Corporation.
Growth is primarily fueled by the WHO’s "End TB Strategy" targets, an increasing incidence of TB in high-burden countries, and the rising need for screening vulnerable populations, such as People Living with HIV (PLHIV) and close household contacts of active TB patients.
While North America currently leads in market share due to advanced infrastructure, the Asia-Pacific region is anticipated to be the fastest-growing market. This growth is driven by high disease prevalence, rapid urbanization, and increasing government investments in healthcare infrastructure in countries like India and China.
The primary challenges include the high cost of IGRA tests compared to traditional skin tests, a lack of necessary laboratory infrastructure in resource-constrained settings, and the clinical difficulty of distinguishing between latent infection and active TB disease.
Digital health integration is a major trend, with the incorporation of AI-powered data analytics, mobile health platforms for remote test reporting, and digital diagnostic platforms. These innovations are improving test interpretation and expanding diagnostic reach into rural and underserved areas.
PLHIV represent one of the most critical application segments. Because this population is at a high risk of latent TB progressing to active disease, global health agencies and NGOs have prioritized regular screening for this group, driving significant demand for sensitive diagnostic solutions.
Key developments include QIAGEN’s partnership with FIND to improve testing accessibility in Africa, bioMérieux’s USD 150 million investment in manufacturing facilities in France, and the US FDA granting breakthrough designation to Thermo Fisher Scientific’s novel digital TB test.
Diagnostic laboratories remain the dominant end-use segment. Their leadership is attributed to their centralized infrastructure, high testing capacity, and ability to manage complex assays and multi-disease workflows essential for national screening programs.
